Chief Financial Officer

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Nuvalent Insider Sold Shares Worth $293,642, According to a Recent SEC Filing

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Nuvalent assumed with a Buy at Guggenheim

Director, Commercial Forecasting and Analytics

Nuvalent, Inc. is an early-stage company focused on creating selective medicines for cancer patients. The Director, Commercial Forecasting and Analytics will lead market research and analytics initiatives to support business decisions for the NSCLC portfolio, providing insights to drive commercial strategy and product positioning.

Sign up with Google

Sign in with Google